The Society annually presents an award to an outstanding
individual in recognition of their contributions and achievements in the resolution of
public environmental concerns. There are no specific criteria, no age limitations,
however, international scientific developments in toxicology are of special interest.
THE INTERNATIONAL SOCIETY OF REGULATORY
TOXICOLOGY AND PHARMACOLOGY
THE 2014 INTERNATIONAL ACHIEVEMENT AWARD TO
Department of Pharmacology and Toxicology
Michigan State University
Diane McColl introduction of Dr. Jay I. Goodman,
I am pleased to announce that Dr. Jay I. Goodman has
been awarded the 2014 ISRTP International Achievement Award.
Dr. Goodman is a Professor in the Department of
Pharmacology and Toxicology, and Faculty Member, at the Center for
Environmental Toxicology, Michigan State University. He is a Diplomate of
the American Board of Toxicology and a Fellow of the Academy of
His research interests are focused on
discerning epigenetic mechanisms underlying carcinogenesis and other
chemical-induced toxicities, and testing the hypothesis that the capacity to
maintain the normal epigenetic status is related inversely to susceptibility
Dr. Goodman has received numerous awards for his
scientific achievements, including
the Distinguished Alumnus Award, Doctoral
Program in Pharmacology, University of Michigan; the John Barnes Prize
Lecture, British Toxicology Society; and the George H. Scott Memorial Award
from the Toxicology Forum, among others.
He is also the first American to serve on a
Earlier this year, Dr. Goodman received the
SOT Merit Award.
Dr. Goodman has participated actively on numerous
SOT Committees and Task Forces, and served as SOT Secretary and SOT
He has participated on review panels and
advisory boards for the NIH, NIEHS, NSF, NTP, US EPA, CDC, American Board of
Toxicology, Academy of Toxicological Sciences, as well as the International
Life Sciences Institute, Health and Environmental Sciences Institute. He
continues to serve on editorial boards and as an advisor on toxicologic
Dr. Goodman will now offer a few comments on why and
how “Toxicology is Part of the Solution.”
Toxicology Is Part
Of The Solution
"First, I would like to express my thanks and
appreciation to the International Society of Regulatory Toxicology and
Pharmacology for awarding me its 2014 International Achievement Award.
Indeed, I am very proud to receive
What excites me about research in
toxicology is that it combines the theoretical with the practical.
pursuing research aimed at discerning the mechanism(s) of action of the
chemical of interest, we learn more about fundamental aspects of
biology. On the practical side, the new knowledge gleaned facilitates
the enhancement of science-based safety assessment of chemicals.
In particular, this permits a rational
approach towards resolving key issues, e.g., a mechanistic basis for the
shape of the dose-response curve (including non-linear,
threshold-exhibiting dose-response curves) and appropriate extrapolation
from test species to humans. Thus, toxicological research plays a
crucial role in enabling the use chemicals (e.g., medicines, consumer
products and agricultural chemicals) to enhance the quality of people’s
lives and the environment.
this lecture I will present the salient aspects of my research in the
area of “epigenetics meets toxicology.”
In particular, my focus is on
understanding the roles that epigenetic alterations play in chemical
carcinogenesis, and testing the hypothesis that susceptibility to
carcinogenesis is related inversely to the capacity to maintain the
normal epigenetic status.
Additionally, I would like to talk
about the future of toxicology and the need to embrace the third
revolution in the biological sciences, i.e., convergence.
All of my remarks are made within the
context of the theme that has guided my scientific career, “toxicology
is part of the solution.”
JAY I. GOODMAN
Professor, Pharmacology and Toxicology
1355 BOGUE ST ROOM
EAST LANSING MI 48824
The involvement of mutagenesis
in carcinogenesis needs to be reconciled with the fact that not all
carcinogens are mutagens and the view that nonmutagenic events also play key
roles in the transformation of a normal cell into a cancer cell. This
apparent paradox can, in part, be resolved by considering the roles that
altered DNA methylation, an epigenetic mechanism, play in carcinogenesis.
Gene expression is not determined only by DNA base sequence; it also
depends on epigenetic mechanisms, i.e., heritable gene-regulating mechanisms
not involving a change in DNA base sequence. Inheritance occurs on two
levels. The transmission of genes either in the somatic sense or from
generation to generation is distinct from mechanisms involved in
transmission of alternative states of gene activity.
Epigenetics describes the latter and involves regulation of temporal
and spatial control of gene activity, e.g., changes in gene expression
during development, imprinting, segregation of gene activities such that
daughters of a cell exhibit different patterns of gene expression, and
mechanisms that permit the somatic inheritance of a specific set of active
and quiescent genes.
DNA methylation (the presence of 5-methylcytosine (5MeC) as 5MeC and
cytosine base pair with guanine. In general, increased methylation of a gene
is associated with deceased transcription (e.g., may silence tumor
suppressor genes, functionally equivalent to inactivation due to point
mutation or allelic loss) and decreased methylation may up-regulate gene
expression (e.g., may increase expression of oncogenes). Thus, altered DNA
methylation can facilitate the aberrant gene expression underlying
The hypothesis being tested in my laboratory is that susceptibility to
carcinogenesis, and perhaps other toxicities, is related inversely to the
capacity to maintain normal patterns of DNA methylation. Particular emphasis
is being placed on discerning novel genes that are involved in
carcinogenesis due to aberrant methylation.
Long Island University,
College of Pharmacy, B.S., 1965
University of Michigan, Ph.D.,
Selected Professional Activities:
completed postdoctoral training at the University of Wisconsin. He has
received the Distinguished Alumnus Award, Long Island University, College of
Pharmacy, 1998; was Elected President of the Society of Toxicology,
1999-2000; the Distinguished Alumnus Award, Doctoral Program in
Pharmacology, The University of Michigan, 2000; gave the John Barnes Prize
Lecture, British Toxicology Society in 2005; and is the recipient of the
Society of Toxicology's Merit Award, 2014. Dr. Goodman is a faculty trainer
for the NIEHS training grant.
(2013) John Fawell, Ph.D.
(2012) Michael L. Gargas, Ph.D.
Michael G. Bird, Ph.D., FRSC
Gio Batta Gori, Ph.D.
(2009) Michael Dourson,
Ph.D., DABT, ATS
Mildred S. Christian, Ph.D., Fellow, ATS
Schwetz, D.V.M., Ph.D.
(2006) Elizabeth I. Anderson,
Jerome H. Heckman, Esq.
(2004) Lester M. Crawford,
(2003) Curtis D. Klaassen,
(1999) Dr. Alan Rulis,
Director, Office of Premarket Approval (OPA)
(1998) Dr. Roger O. McClellan, President, CIIT, Research
Triangle Park, NC
(1997) Dr. Ian C. Munro, Principal, FRCPath
(1996) Dr. John Higginson, Retired Professor of Medicine,
(1995) Robert C. Barnard, Esq., Cleary, Gottlieb, Steen &
(1994) Dr. Philip Abelson, Science Magazine, Washington, DC
(1993) Dr. C. Jelleff Carr, Managing Editor of RTP, Columbia, MD
(1991) Dr. John P. Frawley, Health & Environment
International, Ltd., Wilmington, DE
(1990) Dr. John Doull, University of Kansas Medical Center, Kansas
(1989) Dr. Frederick Coulston, Coulston Foundation, Alamogordo, NM
(1988) Dr. Robert A. Neal, Retiring President of CIIT, Research
Triangle Park, NC
(1987) Dr. Gaston A. Vettorazzi, Geneva, Switzerland and Dr. Frank
C. Lu, Miami, FL, WHO